key: cord-0998780-7x9jzge5
authors: Tarke, Alison; Coelho, Camila H.; Zhang, Zeli; Dan, Jennifer M.; Yu, Esther Dawen; Methot, Nils; Bloom, Nathaniel I.; Goodwin, Benjamin; Phillips, Elizabeth; Mallal, Simon; Sidney, John; Filaci, Gilberto; Weiskopf, Daniela; da Silva Antunes, Ricardo; Crotty, Shane; Grifoni, Alba; Sette, Alessandro
title: SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron
date: 2021-12-28
journal: bioRxiv
DOI: 10.1101/2021.12.28.474333
sha: 6a7724fa66acfdf9bcc8ab80892342c2514f7726
doc_id: 998780
cord_uid: 7x9jzge5

We address whether T cell responses induced by different vaccine platforms (mRNA-1273, BNT162b2, Ad26.COV2.S, NVX-CoV2373) cross-recognize SARS-CoV-2 variants. Preservation of at least 83% and 85% for CD4+ and CD8+ T cell responses was found, respectively, regardless of vaccine platform or variants analyzed. By contrast, highly significant decreases were observed for memory B cell and neutralizing antibody recognition of variants. Bioinformatic analyses showed full conservation of 91% and 94% of class II and class I spike epitopes. For Omicron, 72% of class II and 86% of class I epitopes were fully conserved, and 84% and 85% of CD4+ and CD8+ T cell responses were preserved. In-depth epitope repertoire analysis showed a median of 11 and 10 spike epitopes recognized by CD4+ and CD8+ T cells from vaccinees. Functional preservation of the majority of the T cell responses may play an important role as a second-level defense against diverse variants.

escape. We therefore characterized RBD-specific memory B cell recognition of variants Alpha, Beta, Gamma and Delta ( Figure 3I, Figure S4G ,I). Significant decreases in RBD-specific memory B cell recognition of Alpha (fold change=0.88; P<0.0001), Beta (fold change=0.61; P<0.0001), Gamma (fold change=0.57; P<0.0001) and Delta (fold change=0.77; P<0.0001) were all noted ( Figure 3I) .

Neutralizing antibody titers to variants were measured compared to a D614G reference virus, for the same vaccinated individuals (Figure 3J, Figure S4J ). Neutralization decreases were significant for Alpha (P<0.0001), Beta (P<0.0001), Gamma (P<0.0001) and Delta (P<0.0001) variants ( Figure 3J) . The highest neutralization antibody titers were against D614G, and reductions in neutralizing titers of 2.4-fold, 4.5-fold, 3.8-fold and 3.4-fold against Alpha, Beta, Gamma and Delta variants, respectively were noted ( Figure 3J and Figure S4J) . A similar pattern was observed for COVID-19 convalescent subjects ( Figure  S4K-L) . Spike and RBD binding IgG titers in vaccinated subjects had similar trends to neutralizing antibodies but with smaller differences (Figure 3K -L, Figure S4M-N) . In conclusion, while no significant change in T cell recognition was noted, decreases in memory B cell and neutralizing antibody recognition of all variants analyzed were apparent.

With the recent emergence of the Omicron variant, studies were immediately expanded to include Omicron. We first predicted the impact of variant mutations for CD4 + and CD8 + T cell epitopes experimentally curated in the IEDB (www.IEDB.org)(Grifoni et al., 2021; Vita et al., 2019) ( Table S4 ). In addition to Omicron, we included a wider panel of early and late SARS-CoV-2 variants for comparison.

For CD4 + T cell responses, an average of 95% of the epitopes spanning the entire SARS-CoV-2 proteome were fully conserved (no mutations) across the variants ( Figure 4A ). The Delta variant was not associated with a significant decrease (Figure 4A) , while the fraction of fully conserved epitopes was reduced in Omicron (88%), compared to the other variants (p<0.0001) ( Figure 4A) . A similar result was observed for CD8 + T cell epitopes, with an average 98% overall conservation but 95% for Omicron (P<0.0001) ( Figure 4B ). Considering only spike epitopes, of relevance in the context of vaccination, an average of 91% and 94% CD4 + and CD8 + T cell epitopes were conserved in the various variants. The Omicron variant was associated with the fewest fully conserved spike epitopes for both CD4 + and CD8 + T cells (CD4 + : 72%, P<0.0001; CD8 + : 86%, P<0.0001) (Figure 4C-D) .

These values were conservative estimates of the number of preserved epitopes, since conservative substitutions and changes not impacting HLA binding can still be cross-reactively recognized. Accordingly, we examined the effect of the mutations on the predicted binding affinity of each CD8 epitope for which HLA restriction could be inferred (Figure 4E-G) . Notably, in the majority of cases, the variant-associated mutations were predicted to not impair HLA binding capacity (Figure 4E-G) . Importantly, 72% of the epitopes with Omicron variant mutations were predicted to retain similar HLA class I binding capabilities, which is not dissimilar to other SARS-CoV-2 variants (p=0.8625; Figure 4H ). In conclusion, bioinformatic analyses suggest that the majority of CD4 + and CD8 + T cell epitopes are unaffected by mutations, regardless of whether early or late variants were considered ( Figure 4A-D) , thus suggesting that variant evolution was not driven by T cell escape. In the case of Omicron, the number of totally conserved epitopes is decreased, as expected on the basis of the larger number of spike mutations associated with Omicron. However, the majority of Omicron epitopes (full proteome or spike) were still 100% conserved, and the majority of mutated epitopes were predicted to still be recognizable by T cells.

Next, we experimentally determined the impact of Omicron mutations on T cell responses, in comparison to other variants, in a cohort of individuals vaccinated 5-6 months before donating blood and also in parallel subsequently used for epitope mapping. The overall conservation of memory CD4 + T cell recognition of Omicron spike was 0.84 by AIM and 0.75 by ICS assay (fold change). A significant decrease was observed for Omicron and the magnitude of the reduction was comparable to that of Alpha or Beta variants by AIM, while a significant decrease we observed only for Alpha by ICS (Figure 5A-B ). At the individual subject level, no AIM + CD4 + decreases >3-fold were observed. Cytokine-producing CD4 + T cells decreases >3-fold were observed in 9 of 170 instances (5%) and no instances greater than 10-fold ( Figure 5B) . The conservation of memory CD8 + T cell recognition of Omicron spike was 0.85 by 6 AIM (fold change) and 1.5 by ICS; both were not significant, while significant decreases were observed for Alpha, Beta and Delta by AIM (Figure 5C-D) .

For all timepoints analyzed in this study, we found a very weak inverse correlation between fold change decrease and the magnitude of the spike-specific T cell responses ( Figure S5E-F) , suggesting that overall weaker responses tend to be less frequently associated with decreases in the variants. This might simply reflect weaker responses being associated with a lesser dynamic range and therefore decreases less reliably measured. In any case, it did not support the notion that significant decreases are selectively associated with weak responses. We also examined the notion that weaker responses might be associated with individual HLA allele combinations, utilizing bioinformatic tools specifically designed to detect HLA associations (Paul et al., 2017) . No specific HLA class I or class II alleles were significantly correlated to reduced variant recognition in our cohort (data not shown), but the limited sample size was not powered to detect HLA associations, which usually required substantially larger numbers of observations.

To further examine the molecular mechanism involved in the observed effects of T cell recognition of variant spike epitopes, we selected four donors for in depth spike epitope identification studies and variant analyses (Figure 6A-D, Table S5 ). Each vaccinated donor recognized 5 to 42 (median 11) individual CD4 + T cell epitopes in spike ( Figure 5A ). Approximately 80% of the CD4 + T cell response was associated with epitopes fully conserved in Omicron, with the actual values per donor ranging from 65% to 100% ( Figure 6B ). Each vaccinated donor recognized 6 to 19 (median 10) spike CD8 + T cell epitopes ( Figure 6C ). Approximately 80% of the CD8 + T cell response was associated with epitopes fully conserved in Omicron, with the values per donor ranging from 70% to 100% ( Figure 6D ). These results were in agreement with the bioinformatic analyses (Figure 4) . In sum, these epitope mapping data show how the wide epitope repertoire associated with vaccine-induced responses counterbalances the effect of variant mutations of certain spike epitopes.

Here we analyzed adaptive immunity in vaccinated individuals to a comprehensive panel of SARS-CoV-2 variants, including Delta and Omicron, for multiple vaccines. Our data demonstrate that the vast majority of T cell epitopes are fully conserved, not only in the "early" variants previously analyzed (Collier et Tarke et al., 2021b), but also in newer variants, suggesting that the continued evolution of variants has not been associated with increased escape from T cell responses at the population level.

At the level of the full proteome, which is relevant for natural infection, 95% of reported class II and 98% of class I epitopes were fully conserved by computational analysis. In the case of Omicron, the fraction of epitopes that were fully conserved dropped to 88% for class II and 95% for class I epitopes in the whole proteome. Focused only on spike, relevant in the context of vaccination, 91% of class II and 94% of class I epitopes were still fully conserved. The fraction of totally conserved spike epitopes in Omicron dropped to 72% for class II and 86% for class I epitopes. The higher number of mutated T cell epitopes in spike was expected since many variant mutations are localized in the spike protein. Overall, the majority of T cell epitopes are conserved at the sequence level in all variants analyzed so far, including Omicron. It should be emphasized that an epitope mutation does not preclude cross-reactive recognition of the mutated sequence. To partially address this point, we calculated the fraction of class I epitope mutations predicted to be associated with a decrease in binding affinity to the relevant HLA. We found that, of the mutated epitopes, HLA binding was conserved for 72% of the epitopes. The impact on HLA binding was not different for Omicron epitopes compared to other variants. These observations argue against a model that mutations accumulated in Omicron might be the result of T cell immune pressure at the population level.

T cell recognition of several variants, including Delta and Omicron, was experimentally measured in donors vaccinated with mRNA-1273, BNT162b2 or Ad26.COV2.S. Variant recognition relative to the ancestral sequence was similar in the three different vaccine platforms tested, which is reassuring in terms of the potential implications for protective effects being similar regardless of the vaccine platform considered. A significant higher variability was detected with Ad26.COV2.S, but no clear explanation for this effect was apparent. A significant trend was also noted for more frequent decreases when utilizing the IFNγ production as a readout; while it is possible that this particular function is more impacted in mutated sequences, the measured outcomes may also be related to assay sensitivity limits.

A majority of memory T cells were not impacted by variants' mutations, which is again reassuring in terms of the potential implications for T cell protective effects being similar regardless of the different vaccine cohorts considered. Memory T cell responses to the various variants, including Omicron, were dissected in detail in a cohort of donors 6-7 months following vaccination. The results confirmed that the majority of both CD4 + and CD8 + T cell responses detected by the AIM assay were preserved at this late time point. Some CD8 + T cell response decreases were observed when utilizing the IFNγ production as a readout. Of note, regardless of the assay, Omicron responses were largely preserved in both CD4 + and CD8 + T cells. In depth epitope identification experiments revealed that both CD4 + and CD8 + T cell responses in vaccinated donors were broad, and the data further demonstrated that for each individual donor/variant combination the majority of responses recognized epitopes 100% conserved. These data provide a clear explanation for the limited impact of variant associated mutations on T cell responses.

Adaptive immunity against SARS-CoV-2 consists of multiple branches (Sette and Crotty, 2021). Memory B cell recognition of variants' spikes was reduced in all cases, but the reductions were < 3-fold, including against Delta spike and Beta RBD, demonstrating substantially retained memory B cell recognition of variants (Cho et al., 2021; Goel et al., 2021; Sokal et al., 2021a) . This is consistent with the observations that neutralizing antibody titers against Omicron are generally low in individuals after two doses of mRNA-1273 or BNT162b2 but Omicron neutralizing antibody titers rapidly increase after a third immunization (Liu et al. This data provides reason for optimism, as most vaccine-elicited T cell responses remain capable of recognizing all known SARS-CoV-2 variants. Nevertheless, the data also underline the need for continued surveillance and the potential danger posed by continued variant evolution that could result in 8 further reduction of T cell responses. Incorporation of additional elements eliciting broader T cell responses directed towards more conserved targets into vaccine strategies may be considered as a means to increase vaccine effectiveness against future variants.

The present study is associated with limitations, including the fact that memory B cells were not assessed for Omicron spike binding. A further caveat is that it is unknown what level of epitope conservation is likely to preserve functional T cell responses in vivo. Finally, the current study has not investigated subjects following natural infection.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W. A.T. was supported by a PhD student fellowship through the Clinical and Experimental Immunology Course at the University of Genoa, Italy. We thank Gina Levi and the LJI clinical core for assistance in sample coordination and blood processing. We gratefully thank the authors from the originating laboratories responsible for obtaining the specimens, as well as the submitting laboratories where the genome data were generated and shared via GISAID, and on which this research is based. We would like to thank Vamseedhar Rayaprolu and Erica Ollmann Saphire for providing the recombinant SARS-CoV-2 Receptor Binding Domain (RBD) protein used in the ELISA assay. The number of epitopes that are fully conserved, or that are associated with single or multiple mutations,insertions/deletions was computed across SARS-CoV-2 variants. The analysis shown represents the breakdown of conserved and mutated CD4 + (A, C) and CD8 + epitopes (B, D) for all SARS-CoV-2 proteins (A-B) and spike protein only (C-D). The percentage of conserved epitopes was calculated for each variant separately. Average conservancy and standard deviations were calculated for all the variants, or separately for early variants, more recent SARS-CoV-2 variants, and Omicron. (E-H) The predicted HLA binding affinities of mutated versus ancestral sequences of CD8 + epitopes are shown, based on the epitope/HLA combinations curated in the IEDB data as of July 2021. Predicted HLA binding values to the relevant HLA allelic variant were calculated using the IEDB recommended The fold change of all cytokine + CD8 + T cells as calculated from the IFNγ + , TNFα + , IL-2 + , or Granzyme B + CD8 + T cells. Significance of fold change decreases for each variant was assessed by Wilcoxon Signed Rank T test compared to a hypothetical median of 1. See also Figure S5 and Table S1

Figure 6. Impact of SARS-CoV-2 variants on spike epitope repertoires of fully vaccinated donors 5-6 months after vaccination. The response to SARS-CoV-2 variants was assessed in individuals 5-6 months after full vaccination with mRNA-1273 (circles), BNT162b2 (triangles) and Ad26.COV2.S (squares). (A) CD4 + and (C) CD8 + T cell epitope repertoires were determined for 4 mRNA-1273 vaccinees (no CD8 epitopes were identified for donor 6263). The percent of T cell response associated with conserved epitopes for each individual donor for (B) CD4 + and (D) CD8 + T cells is shown for each variant assessed. Each graph shows the total response detected with the ancestral spike MP, and the summed total response detected against each of the individual epitopes identified. The histograms show the % of the total response accounted from each epitope where black bars indicate non-mutated epitopes, while mutated epitopes are represented by open bars, with color coding further indicating which variant mutations are associated with the epitope. Based on these data the fraction of the total response to each variant that can be accounted for by nonmutated epitopes can be calculated, as also shown in the graph. See also Table S1, S2, S3 and S5.

Please refer to the Lead Contact (Alessandro Sette, alex@lji.org) for further information pertaining to availability of resources and reagents.

Upon specific request and execution of a material transfer agreement (MTA) to the Lead Contact or to A.G., aliquots of the peptide pools utilized in this study will be made available. Limitations will be applied on the availability of peptide reagents due to cost, quantity, demand and availability.

All the data generated in this study are available in the published article and summarized in the corresponding tables, figures and supplemental materials.

The genome sequences for the B.1.1.7, B.1.351, P.1. and B.1.427/429 variants were selected as previously described (Tarke et al., 2021b). For the additional variants selected, the sequence variations in the variant viruses were derived by comparison with Wuhan-1 (NC_045512.2). All mutated amino acids in the different variants are outlined in Table S3 . To determine the impact of the selected variants on T cell epitopes, CD4 and CD8 T cell epitopes were extracted from the IEDB database (www.IEDB.org)(Vita et al., 2019) on July 8 th 2021 using the following query: Organism: SARS-CoV2 (ID:2697049, SARS2), Include positive assays only, No B cells, No MHC assays, Host: Homo sapiens (human) and either MHC restriction type: Class I for CD8 epitopes or Class II for CD4 epitopes. Additional manual filtering was performed on the extracted datasets allowing only epitopes of 9-14 residues in size for class I and 13-25 residues for class II. This resulted in a total of 446 and 1092 epitopes for CD4 and CD8, respectively. The binding capacity of SARS-CoV-2 T cell epitopes, and their corresponding variantderived peptides, was determined for their putative HLA class I restricting allele(s) in a smaller epitope subset (n=833) where information regarding allele restriction was available. Prediction analyses for class I were determined utilizing the NetMHCpan EL4. 

The La Jolla Institute for Immunology (LJI) Clinical Core recruited healthy adults who had received the first and, when applicable, second dose of a COVID-19 vaccination among the mRNA-1273, BNT162b2, Ad26.COV2.S or NVX-CoV2373 available vaccinations. At the time of enrollment in the study, all donors gave informed consent. The LJI Clinical Core facility has collected blood draws under IRB approved protocols (LJI; VD-214) when possible two weeks after each vaccine dose administered (timepoint 1 and timepoint 2) and/or 3.5 months after the last dose received (timepoint 3). All donors had their SARS-CoV-2 antibody titers measured by ELISA, as described below. Additional information on gender, ethnicity, age and timepoint of collection of the vaccinee cohorts are summarized in Table S1 .

The LJI Clinical Core performed blood collection and sample processing based on SOPs previously established and described (Dan et al., 2021; Tarke et al., 2021a) . Whole blood was collected in heparin coated blood bags, and the cellular fraction was separated from plasma by a centrifugation at 1850 rpm for 15 minutes. The plasma was consequently collected and stored at -20°C for serology assays, while the cellular fraction underwent density-gradient sedimentation to obtain the PBMCs using Ficoll-Paque (Lymphoprep, Nycomed Pharma, Oslo, Norway)(Grifoni et al., 2020). Isolated PBMCs were stored in liquid nitrogen in cryopreserved cell recovery media containing 90% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories, Logan UT) and 10% DMSO (Gibco) until cellular assays were performed. HLA typing was performed by an ASHI-accredited laboratory at Murdoch University (Western Australia) for Class I (HLA A; B; C) and Class II (DRB1, DRB3/4/5, DQA1/DQB1, DPB1), as previously described(Tarke et al., 2021a) ( Table S2) . Pheresis blood donations from an additional cohort of mRNA vaccinees were provided by the contact research organization (CRO) BioVIT and collected under the same IRB approval (VD-214) at LJI.

SARS-CoV-2 serology was performed for all plasma samples collected as previously described(Rydyznski Moderbacher et al., 2020). Briefly, 1 ug/mL SARS-CoV-2 spike (S) Receptor Binding Domain (RBD) was used to coat 96-well half-area plates (ThermoFisher Cat#3690), which were then incubated at 4°C overnight. After blocking the plates the next day at room temperature for 2 hours with 3% milk in phosphate buffered saline (PBS) and 0.05% Tween-20, the heat-inactivated plasma was added for an additional 90-minute incubation at room temperature, followed by incubation with the conjugated secondary antibody. Plates were read on the Spectramax Plate Reader at 450 nm using the SoftMax Pro. For data analysis of SARS-CoV-2 serology, the limit of detection (LOD) was defined as 1:3 while the limit of sensitivity (LOS) was established based on uninfected subjects, using plasma from normal healthy donors that did not receive COVID-19 vaccination. The SARS-CoV-2 pseudovirus (PSV) neutralization assay was performed for timepoint 3 samples as previously described ( . Pretitrated recombinant virus for each variant were incubated with serially diluted human heat-inactivated plasma at 37°C for 1-1.5 hours. Confluent VERO cell monolayers were added and incubated for 16 hours at 37°C in 5% CO2 then fixed in 4% paraformaldehyde in PBS pH 7.4 (Santa Cruz, Cat# sc-281692) with 10 μg/ml Hoechst (Thermo Scientific, Cat#62249). Cells were imaged using a Cell Insight CX5 imager to quantify the total number of cells and infected GFP expressing cells to determine the percentage of infection. Neutralization titers (inhibition dose 50-ID50) were calculated using the One-Site Fit Log IC50 model in Prism 8.0 (GraphPad), and calibrated to WHO international standard (20/268). Samples that did not reach 50% inhibition at the lowest serum dilution of 1:20 were considered as non-neutralizing and were calibrated as 10.73 IU/mL. . In this study, we performed both assays separately at timepoint 3, while we combined them for timepoints 1 and 2. To assess the best protocol for AIM+ICS assay, we carried out the three assays in parallel in the same samples ( Figure S1 ). The best assay configuration to retain AIM marker expression and simultaneously detect cytokines required the addition of CD137 antibody to culture as described in detail below. Figure  S1 shows also the comparison of this AIM+ICS protocol with the classical AIM or ICS assays; no 13 significant differences are observed amongst protocols, suggesting that the combined assay can be used to simultaneously detect AIM + cells and the cytokine profile. In all assays, PBMCs were cultured in the presence of SARS-CoV-2-specific (ancestral or variant) MPs [1 μg/ml] in 96-well U-bottom plates at a concentration of 1x10 6 PBMC per well. As a negative control, an equimolar amount of DMSO was used to stimulate the cells in triplicate wells phytohemagglutinin (PHA, Roche, 1μg/ml) stimulated cells were used as positive controls. After incubation for 24 hours at 37°C in 5% CO2 cells were either stained for AIM markers only or an additional incubation of 4 hours was carried out by adding Golgi-Plug containing brefeldin A, Golgi-Stop containing monensin (BD Biosciences, San Diego, CA) and in the case of the AIM+ICS assay combined CD137 APC antibody was additionally added in culture (2:100; Biolegend Cat# 309810). In all assays, cells were stained on their surface for 30 min at 4°C in the dark. For AIM assays, cells were then acquired directly, while for both ICS and AIM+ICS assays, cells were additionally fixed with 1% of paraformaldehyde (Sigma-Aldrich, St. Louis, MO) permeabilized and blocked for 15 minutes followed by intracellular staining for 30 min at room temperature. All samples were acquired on a ZE5 5-laser cell analyzer (Bio-Rad laboratories) and analyzed with FlowJo software (Tree Star Inc.). The gates for AIM or cytokine positive cells were drawn relative to the negative and positive controls for each donor. A representative example of the gating strategy for AIM, ICS or AIM+ICS assays is depicted in Figure S1 . Specifically, lymphocytes were gated, followed by single cells determination. T cells were gated for being positive to CD3 and negative for a Dump channel including in the same colors CD14, CD19 and Live/Dead staining. The CD3 + CD4 + and CD3 + CD8 + were further gated based on OX40 + CD137 + and CD69 + CD137 + AIM markers, respectively. For ICS, CD3 + CD4 + and CD3 + CD8 + cells were further gated based on a combination of each cytokine (IFNγ, TNFα, IL-2, Granzyme B) with CD40L or FSC-A, respectively ( Figure S1 ). To the total cytokine response and T cell functionality was calculated from Boolean gating of single cytokines or Granzyme B that was applied to CD3 + CD4 + or CD3 + CD8 cells. In the resulting data generated from the AIM and ICS T cell assays, the background was removed from the data by subtracting the average of the % of AIM + or Cytokine + cells plated in triplicate wells stimulated with DMSO. The Stimulation Index (SI) was calculated by dividing the % of AIM + cells after SARS-CoV-2 stimulation with the average % of AIM + cells in the negative DMSO control. An SI greater than 2 and a LOS of 0.03% or 0.04 % AIM + CD4 + or CD8 + cells, respectively, after background subtraction was considered to be a positive response based on the median twofold standard deviation of T cell reactivity in negative DMSO controls. For ICS, an SI greater than 2 and a LOS of 0.01% or 0.02% ICS + CD4 + or CD8 + cells, respectively, after background subtraction was considered to be a positive response based on the median twofold standard deviation of T cell reactivity in negative DMSO controls for all timepoints, except timepoint 4 that had an LOS of 0.01% for CD8 + T cells.

Detection of antigen-specific B cells by flow cytometry was performed using B cell probes consisting of SARS-CoV-2 viral proteins conjugated with fluorescent streptavidin, as previously described by our group (Dan et al., 2021) . Spike and RBD recombinant proteins used in this study are described in the Key Resource Table. Two separate flow cytometry panels were used to identify spike or RBD variants. To enhance specificity, identification of both WT spike and WT RBD B cells was performed using two fluorochromes for each protein, prior to gating on variant B cells. For that, biotinylated WT SARS-CoV-2 spike was incubated with Streptavidin in either BV711 (BioLegend, Cat# 405241) or BV421 (BioLegend, Cat# 405225) at a 20:1 ratio (~6:1 molar ratio) for 1 hour at 4°C. In a separate panel, biotinylated WT RBD was also conjugated with streptavidin BV711 (BioLegend, Cat# 405241) or streptavidin PE-Cy7 consisting in 5µ of biotin (Avidity, catalog no. Bir500A) to avoid cross reactivity among probes, 20 ng of decoy probe, 416 ng of spike and 20.1 ng of RBD per sample, diluted in Brilliant Buffer (BD Biosciences, Cat# 566349) and incubated for 1 hour at 4°C, protected from light. After washing with PBS, cells from both spike and RBD panels were incubated with surface antibodies diluted in Brilliant Buffer, for 30 at 4°C, protected from light. Viability staining was performed using Live/Dead Fixable Blue Stain Kit (Thermo Fisher, Cat# L34962) diluted 1:200 in PBS and incubation at 4°C for 30 minutes. Acquisition was performed on Cytek Aurora and analyses were made using Flow Jo v. 10.7.1 (BD Biosciences). The frequency of Variants-specific memory B cells was expressed as a percentage of WT spike or RBD memory B cells (Singlets, Lymphocytes, Live, CD3-CD14-CD16-CD56-CD19+ CD20+ CD38int/-, IgD-and/or CD27+ spike or RBD BV711+, spike or RBD BV421+). PBMCs from a known positive control (COVID-19 convalescent subject) and an unexposed subject were included to ensure consistent sensitivity and specificity of the assay. Streptavidin PE-Cy5.5 (Thermo Fisher Scientific, Cat# SA1018) was used as a decoy probe to minimize background by eliminating SARS-CoV-2 nonspecific streptavidinbinding B cells. 1 1.1 1.1 1.1 1.0 1.0 1.0 1 1 1.1 1.1 1.1 1.0 1.0 1.0 1 in v a ri a n ts in v a ri a n ts in v a ri a n ts in v a ri a n ts in v a ri a n ts T cells   P26S  P26S  Q25R  H69-; V70-; A67V  D138Y; G142D;  V143-145del   R190S  L241-, L242-, A243-S371L, S373P, S375F  N440K  T547K  H655Y  T547K  Q677H; N679K  A701V  T716I   N764K   G769V; N764K   F888L  Q954H  N969K Mutated epitope 1, 2, 3, 5 and 6 . Characteristics of the donor cohorts enrolled in this study. 1, 2, 3, 5 and 6 . HLA typing of the cohort studied. I  nsp3  1180  T  I  nsp3  1189  T  I  nsp3  1265  S  -nsp3  1266  L  I  nsp3  1412  I  T  nsp3  1429  T  N  nsp3  1469  P  S  S  nsp3  1569  F  V  nsp3  1778  N  S  nsp3  1892  A  T  nsp4  395  S  T  nsp4  399  K  E  nsp4  438  L  P  P  P  nsp4  446  A  V  nsp4  492  T  I  I  I  I  nsp5  90  K  R  nsp5  132  P  H  nsp5  193  A  V  nsp6  49  I  V  nsp6  77  T  A  nsp6  106  S  -------nsp6  107  G  -------nsp6 108 ORF7a  120  T  I  ORF8  11  T  I  I  K  ORF8  27  stop  ORF8  38  P  S  ORF8  51  A  S  ORF8  67  S  F  ORF8  92  E  K  ORF8 121 1. Related to Figures 1, 2, 3, 5 and 6 

E L D S F K E E L F C N D P F L G V S R L D K V E A E V S T G S N V F Q T R G T H W F V T Q R N A T N V V IK V V G Y L Q P R T F F A S T E K S N I F T IS V T T E I N A T N V V IK V N Q K L IA N Q F Q S A P H G V V F IA N Q F N S A I N A T N V V IK V V V F L H V T Y V S T Q D L F L P F N T S N Q V A V L Y T N S F T R G V Y L G A E N S V A YG IY Q T S N F R V Q P T E S S V A S Q S II A Y T M S L G S II A Y T M S L G A E N S V T N F T IS V T T E IL P V S IP F A M Q M A Y RR F A S V Y A W N R K R IS N K R IS N C V A D Y S V L Y N S V L Y N S A S F S T F K C Y K L N D L C F T N V Y A D S F P D D F T G C V IA W NP A Y T N S F T R G V Y Y P D S F T R G V Y Y P D K V F R S S V L H S T Q D L F L P F F S V V IK V C E F Q F C N D P F S IA IP T N F T IS V T T E T N F T IS V T T E IL P V S IL P V S M T K T S V D C T M S F IE D L L F N K V T L A D A G F IK Q Y G D C L G D IA H W F V T Q R N F Y E P Q II Q R N F Y E P Q II T T D N T E P Q II T T D N T F V S G N T T D N T F V S G N C D V V I T V Y D P L Q P E L D S F K E L Q P E L D S F K E E L D K Y D S F K E E L D K Y F KR T Q L P P A Y T N S F T R G P A Y T N S F T R G V Y Y P D K V F R S S V L H S T Q D L F L P F F S N V T W F H A IH V C E F Q F C N D P F L G V Y Y C T F E Y V S Q P F L M D L E L M D L E G K Q G N F K N L R E F V F K N ID G Y F K IY S N ID G Y F K IY S K H T P I IG IN IT R F Q T L L A L H S G W T A G A A A Y Y V G Y L G A A A Y Y V G Y L Q P R T F Y V G Y L Q P R T F L L K Y N G IY Q T S N F R V Q P T E S S N F R V Q P T E S IV R F P Y A W N R K R IS N C V A D Y S A S F S T F K C Y G V S P T K L N D L C F T N V Y A D S F Y A D S F V IR G D E V R Q I G C V IA W N S N N L D S K V T N L V K N K C V N F N F N G F N F N G L T G T G V L T E S L T G T G V L T E S N K K F L N V F Q T R A G C L IG A E H IG A G IC A S Y Q T Q T N S S V A S Q S II A Y T M S L G S II A Y T M S L G A E N S V A Y S N N S IA IP T N F T I S T E C S N L L L Q Y G S F C N L L L Q Y G S F C T Q L N R T Q L N R A L T G IA V E Q D V F A Q V K Q IY K T P P IK T D E M IA Q Y T S A L L A G A Q Y T S A L L A G T IT S G T IT S G W T F G A G A A L Q G A A L Q IP F A M Q M A Y R IP F A M Q M A Y R F N G IG Q M A Y R F N G IG V T Q N V K L IA N Q F N S A IG K IQ V V N Q N A Q A L N T L V K Q A Q A L N T L V K Q L S S N F V Q ID R L IT G R L Q S L Q T T A P AF - - - - - - -I L S 5 L F S 13 S I S 18 L F F S 19 T R S 20 T N S 26 P S S 52 Q R S 67 A V S 69 H - - S 70 V - - S 75 G V S 76 T I S 80 D A G S 95 T I I I S 138 D Y S 142 G D S 143 V - S 144 Y - S - S 145 Y - N - S 152 W L C - S 154 E K S 157 F S S 190 R S S 211 N - S 212 L I S 214 ins EPE S 215 D G/H S 241 L - S 242 L - S 243 A - S 246 R N S 247 S - S 248 Y - S 249 L - S 250 T - S 251 P - S 252 G - S 253 D - G S 339 G D S 346 R K S 371 S L S 373 S P S 375 S F S 417 K N T N S 440 N K S 446 G S S 452 L R R Q R R S 477 S N S 478 T K K K S 484 E K K Q K K K K A S 490 F S S 493 Q R S 496 G S S 498 Q R S 501 N Y Y Y Y Y S 505 Y H S 547 T K S 570 A D S 614 D G G G G G G G G G G G G G G S 655

Gating strategy for T cell AIM, ICS, and AIM+ICS assays included in this study. Spike-specific responses are measured for both CD4 + and CD8 + T cells within the same donors using the indicated AIM markers or cytokines. (B-C) Validation of a combined AIM/ICS assay. The addition of a cocktail of Brefeldin and Monesin in the ICS assay significantly decreases the detection of AIM markers, while the inclusion of the CD137 antibody in culture concomitantly, repristinates the response (B) and does not impact the IFNγ detection (C). Data are shown after background subtraction and stimulation index > 2. Statistical analyses are performed using a paired Wilcoxon test. (D-E) Representative gating strategy for the memory B cell assays using spike-protein or RBD, respectively. donors 70 69 69 70 70 70 70 70 69  Frequency 100 99 99 100 100 100 100 100 99   31 31 31 31 31 31 31 31 31  100 100 100 100 100 100 100 100 100   27 27 27 27 27 27 27 27 27  100 100 100 100 100 100 100 100 100   12 11 11 12 12 12 12 12 11  100 92 92 100 100 100 100 100 The sum of CD4 + CD40L + , IFNγ + , TNFα + , IL-2 + , or Granzyme B+ T cells is shown. For CD8 + T cells, (C) the magnitude of AIM + CD8 + T cells is shown and (D) the total cytokine + CD8 + T cells calculated by summing the IFNγ + , TNFα + , IL-2 + , or Granzyme B + CD8 + T cells. COVID-19 mRNA-1273 (circles), BNT162b2 (triangles), Ad26.COV2.S (squares), and NVX-CoV2373 (diamonds) vaccine recipients were assessed for T cell responses to variant Spikes by AIM assay at various timepoints ranging from 2 weeks after the first dose to 5-6 months after the last dose of vaccination. The correlation of magnitude and fold-change values (E) AIM + CD4 + or (F) CD8+ T cells was analyzed for all timepoints combined. R and p values are the results of a Pearson correlation. 17 17 17 17 17 17 17 17 17 17 Frequency 89 100 100 100 100 100 100 100 100 100 100 # of pos donors 12 11 10 12 12 11 11 12 10 11

Beyond Omicron: what's next for COVID's viral evolution

Broadly neutralizing antibodies overcome SARS-CoV

Omicron antigenic shift. bioRxiv

Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate. medRxiv

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

IEDB-AR: immune epitope database-analysis resource in 2019

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung

 Table S5 . Related to Figure 6 . List of class II and class I epitopes identified in vaccinated apheresis donors. Information on the mutations within these epitopes when applicable and to which variants they belong are included.